Svas Biosana S.p.A. (IT:SVS) has released an update. Svas Biosana S.p.A. reported a 5.3% year-over-year increase in consolidated revenues, reaching €85.9 million as of September 30, 2024. The company attributes
Svas Biosana S.p.A. (IT:SVS) has released an update. Svas Biosana S.p.A. reported a 5.3% year-over-year increase in consolidated revenues, reaching €85.9 million as of September 30, 2024. The company attributes
Svas Biosana S.p.A. (IT:SVS) has released an update. Svas Biosana S.p.A., a prominent player in the healthcare sector, has acquired 2,409 of its own shares as part of a buyback
Svas Biosana S.p.A. (IT:SVS) has released an update. Svas Biosana S.p.A., a prominent player in the healthcare sector listed on Euronext Growth Milan, executed a share buyback program, purchasing 1,611
In a report released today, Davide Longo from TP ICAP MIDCAP maintained a Buy rating on Svas Biosana S.p.A. (SVS – Research Report), with a price target of €14.20. Davide
Svas Biosana S.p.A. (SVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 5. Analyst Mickael Daponte from TP ICAP MIDCAP maintained a